Skip to main content
. 2023 Dec 31;14(1):e12327. doi: 10.1002/clt2.12327

TABLE 1.

Demographic and laboratory data of the patients with ABPM‐Sc and ABPA.

ABPM‐Sc ABPA p a
n (%) 30 46
Age at onset of ABPM, y 59 (43–69) 67 (51–71) 0.10
Women, n (%) 20 (67) 27 (59) 0.63
Asthma, n (%) 15 (50) 32 (70) 0.10
Age at onset, years 27 (9–50) 32 (12–50) 0.94
Treatment step (1–2/3–5, n [%]) 10/4 (71/29) 8/22 (27/73) 0.008
Duration between onset of asthma and ABPA, years 11 (3–42) 30 (11–41) 0.12
Laboratory data at diagnosis
Peripheral blood eosinophil counts (/μL) 655 (381–1162) 983 (472–1505) 0.15
Serum IgE levels (IU/mL) 2020 (471–5797) 1954 (530–4583) 0.92
A. fumigatus‐specific IgE, UA/mL 0.80 (0.10–3.34) 11.20 (3.29–30.05) <0.001
A. fumigatus‐specific IgG, mgA/L NA 68.5 (28.8–125.8)
Positive serological tests
A. fumigatus‐specific IgE, n (%) 19 (66) b 45 (98) <0.001
A. fumigatus‐specific precipitin/IgG, n (%) 7 (30) c 40 (87) <0.001
S. commune‐specific IgE, n (%) 11 (92) d NA
S. commune‐specific precipitin/IgG, n (%) 11 (85) e NA
Pulmonary function test
FVC, %predicted 94 (86–106) 99 (82–113) 0.99
FEV1, %predicted 98 (77–109) 80 (65–92) 0.008
FEV1/FVC, % 77 (72–81) 70 (61–80) 0.03
Thoracic computed tomography findings
Central bronchiectasis, n (%) 25 (83) 28 (61) 0.04
Mucus plugs, n (%) 28 (93) 40 (87) 0.47
High attenuation mucus, n (%) 22 (76) 27 (59) 0.14
Infiltration/GGO, n (%) 24 (80) 43 (94) 0.14
Fibrotic/cystic change, n (%) 0 (0) 8 (17) 0.02

Note: Values are medians (interquartile range) or the proportion of patients in each study group, if not otherwise specified.

Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; ABPM‐Sc, ABPM culture positive for S. commune; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GGO, ground‐glass opacity; Ig, immunoglobulin; NA, not assayed.

a

Between the two groups.

b

n = 29.

c

n = 23.

d

n = 12.

e

n = 13.